Clinical Trials Browser

Phase 2 × Thyroid Carcinoma, Anaplastic × 90 days × Clear all

NCT03449108 2026-05-22

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

BreastEndocrineGynecologicHead & NeckSarcoma

Bone Neoplasms, Ovarian Neoplasms, Sarcoma, Osteosarcoma, Giant Cell Tumor of Bone, Histiocytoma, Malignant Fibrous, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT04759911 2026-05-20

Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer

Phase 2 Active not recruiting

30 enrolled

EndocrineHead & Neck

Thyroid Cancer, Papillary, Thyroid Neoplasms, Carcinoma, Medullary, Thyroid Carcinoma, Anaplastic

NCT07470489 2026-04-16

Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer

Phase 2 Not yet recruiting

12 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic

NCT05696548 2026-04-09

Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)

Phase 2 Active not recruiting

51 enrolled

EndocrineHead & Neck

Thyroid Carcinoma, Anaplastic